| Access to an integrated network of high technology imaging capabilities
at both pure research and clinical sites. Click Here for the Neuroimaging Platform Leaders Report 2003/2004 This platform aims to provide access to a network of high cost, high
technology imaging capabilities at both pure research and clinical sites.
A substantial amount of funding has been used in recent years to build
significant, state-of-the-art neuroimaging facilities. These pre-existing
facilities, each with specific capabilities, have been integrated to form
the core of the Neuroimaging platform. |
| Optimise and coordinate access to an integrated network of high-cost, advanced technology imaging capabilities | |
| Provide educational and consultancy services to neuroscientists and industry partners | |
| Attract new business through the creation of technique specific centres | |
| Provide drug evaluation services for the development of new drugs by the pharmaceutical industry |
Facilities & Expertise |
| Magnetic resonance imaging and spectroscopy (MRI & MRS) at 1.5 Tesla and 3 Tesla | |
| Diffusion and diffusion tensor imaging | |
| T2 Relaxometry | |
| Functional magnetic resonance imaging at 4.7 Tesla | |
| Real time functional imaging to map brain activity during experimentally controlled cognitive and motor tasks | |
| Positron emission tomography (PET) and SPECT imaging with state-of-the-art dual and triple head SPECT cameras and two PET Cameras (one of which is a "next generation" GSO crystal based PET camera with an integrated CT scanner) | |
| Steady-State Probe Topography (SSPT) | |
| Computed Topography (CT or CAT), Ultrasound, Angiography, Fluroscopy, Mammography and General X-Ray | |
| Patient holding facilities allowing acute neurological patients to be studied in a safe environment | |
| Animal holding facilities for both small and large animals | |
| Access to a drug evaluation services | |
| Access to processes involved in developing a compound for administration to humans, including FDA approved toxicity studies, small animal pharmacological studies of the labelled compound and Ethics Committee approval for human studies. |
Key Personnel |
| Professor Graeme Jackson (Platform Leader) | Brain Research Institute |
| Dr Christopher Rowe | Nuclear Medicine and Centre for PET, Austin and Repatriation Medical Centre |
| Professor David Crewther | Brain Sciences Institute |
| DR Gary Egan | Howard Florey Institute |
| Associate Professor Trish Desmond | Department of Radiology, Royal Melbourne Hospital |
| DR Stacey Georgen | Department of Neurology, Monash Medical Centre |
Key Achievements 2002-03 Royal Melbourne Hospital The Brain Imaging Lab (Royal Melbourne) has undergone a major upgrade in the 2002-03. The focus has been switching to Linux as a viable platform to run all software. A Dell Poweredge 6650 server has been purchased with 32Gb memory, 4 Xeon
2.8Gbz processors, and 1 terrabyte of storage space. There are also three
new Dell Optiplex SX270 PC's (2.4Ghz P4, with 512Mb RAM) and 19"
monitors for students and staff to use. Upgrades to the latest versions
of Analyze, MEDx and IDL software have also been made. The Brain Research Institute has undergone a significant upgrade to the facilities. Building works have been completed on the extension to the current MRI building that will provide a new and exciting focus for studies being performed at the BRI. Some of the new facilities include: |
| A new central reception and waiting area | |
| Dedicated private interview/examination rooms | |
| Clinical support facilities and patient holding areas | |
| Ambulance and patient transport facilities | |
| Animal holding area | |
| New meeting rooms and offices |
Technical changes have also accompanied the construction of the new building, with the recent delivery of a dual tuned Sodium/Hydrogen coil. Coupled with our ongoing developments in Diffusion Tensor and Phosphorus imaging they have established a new, powerful and comprehensive battery of imaging techniques. The installation of the new GE body coil into the existing system is planned for the near future as well. The new system configuration will significantly enhance our capabilities to support research in an even wider variety of studies (eg. stroke, cardiac, oncology, intensive care, anaesthetics) in the future. Howard Florey MR Facility |